List of AI News about Isomorphic Labs
| Time | Details |
|---|---|
|
2026-11-20 12:11 UTC |
Isomorphic Labs and Merck partner to design new cancer drug
According to Isomorphic Labs and a post by Demis Hassabis cited by X, Isomorphic Labs entered a strategic research collaboration with Merck to design a new cancer drug using frontier AI and Merck’s development expertise. |
|
2026-11-17 04:06 UTC |
Isomorphic Labs secures $5B to accelerate AI drug design
According to a post by Demis Hassabis on X, Isomorphic Labs raised $5B to advance AI-driven, first-principles drug design aimed at cutting time and cost in new medicine discovery. |
|
2026-10-07 07:53 UTC |
Isomorphic Labs Joins Virtual Biology Initiative
According to demishassabis, Isomorphic Labs joins VBI to build open biology resources accelerating disease research, per Isomorphic Labs’ announcement. |
|
2026-07-16 03:44 UTC |
DeepMind Partners Isomorphic Labs on Biosecurity
According to GoogleDeepMind, a new partnership with Isomorphic Labs deploys frontier AI for proactive bioresilience and global health defenses. |
|
2026-05-12 05:50 UTC |
Isomorphic Labs Secures $2.1B to Turbocharge Drug Discovery
According to @demishassabis, Isomorphic Labs raised $2.1B to accelerate AI-driven drug discovery building on AlphaFold, expanding partnerships and pipelines. |
|
2026-02-10 14:49 UTC |
Isomorphic Labs’ New Drug-Design System Doubles AlphaFold 3 on Hardest Cases — 2026 Analysis and Biopharma Impact
According to The Rundown AI on X, Isomorphic Labs’ drug-design system more than doubled AlphaFold 3 performance on the hardest protein-ligand cases, signaling major gains in structure-based drug discovery; the post also notes Demis Hassabis previously won the Nobel Prize for AlphaFold and quoted his 2025 remark, “One day maybe we can cure all disease with the help of AI.” As reported by The Rundown AI, this leap suggests faster hit identification, improved binding predictions, and shorter lead optimization cycles for pharma pipelines. According to the cited post, the results highlight commercial opportunities in licensing AI-native discovery platforms, partnering with big pharma for target classes with sparse data, and deploying active learning loops to cut wet-lab iteration costs. |
|
2026-02-10 07:32 UTC |
DeepMind’s Demis Hassabis on Google’s AI strategy and drug discovery push: 5 takeaways and 2026 business outlook
According to @demishassabis, who shared Fortune’s cover story interview by @agarfinks, Demis Hassabis outlines DeepMind’s roadmap across frontier models, scientific AI, and healthcare. As reported by Fortune, Google DeepMind is scaling multimodal foundation models while integrating them with Alphabet’s product stack to drive monetization in Search, Cloud, and Android. According to Fortune, DeepMind’s Isomorphic Labs is advancing AI-first drug discovery by combining protein structure prediction and generative design to shorten preclinical cycles and improve hit rates with pharma partners. As reported by Fortune, the strategy emphasizes safety research, evaluation benchmarks, and controlled deployment to enterprise customers via Google Cloud. According to Fortune, commercial opportunities highlighted include AI copilots for knowledge work, bioinformatics services for pharma R&D, and custom model hosting for regulated industries, with a focus on reliability and cost efficiency. |
|
2026-02-10 06:03 UTC |
Isomorphic Labs’ AI Drug Design Engine Pushes SOTA Benchmarks: 2026 Progress Analysis for In‑Silico Discovery
According to @demishassabis on X, Isomorphic Labs’ AI-driven drug design engine has advanced the state of the art across key in‑silico discovery benchmarks, showing major gains in accuracy and capabilities critical for computational drug design (source: Demis Hassabis on X, Feb 10, 2026). As reported by the same post, the effort is led by Max Jaderberg and the Isomorphic Labs team, implying improvements that could accelerate hit identification and lead optimization workflows for pharma R&D. According to the X post, these benchmark gains suggest stronger structure-based modeling and generative design performance, offering business opportunities in faster preclinical triage, reduced wet‑lab iterations, and scalable virtual screening partnerships with biopharma. |
|
2026-01-21 03:00 UTC |
Isomorphic Labs and J&J Innovation Partner to Accelerate AI Drug Discovery for Challenging Disease Targets
According to Isomorphic Labs (@IsomorphicLabs), the company has entered into a strategic partnership with Johnson & Johnson Innovation (@JNJInnovation) to leverage Isomorphic's AI drug design engine alongside J&J’s robust drug development capabilities. This collaboration aims to address historically difficult-to-drug disease targets by integrating cross-modality and multi-target research strategies. The partnership is expected to accelerate the path to new medicines and represents a significant advancement in digital biology, potentially unlocking novel molecules that traditional methods might overlook (source: @IsomorphicLabs, https://x.com/IsomorphicLabs/status/2013583586784387193). |